New Multi-Tenant Cloud Platform Gives Life Science Organizations Complete Clinical Operations and Data Management Capabilities in a Convenient,…
Learn MoreLifeSphere® Safety MultiVigilance is the only E2B R3 compliant multi-tenant cloud solution in the safety market. Customers already…
Learn MoreAs different regulatory authorities have different timelines for adoption of these standards, E2B(R2) E2B(R3) will have to coexist. But having to operate two solutions creates huge complexities, unless you find a solution compliant with both. ArisGlobal LifeSphere Safety MultiVigilance is the only drug safety database solution provider thus far to provide full compliance to E2B R2 and E2B R3 standards for both import and export.
Learn MoreOver 200 Life Sciences organizations worldwide are adopting ArisGlobal’s LifeSphere Safety™ multi-tenant cloud platform to achieve E2B(R3) compliance by November 2017 EMA deadline. Within that platform, ArisGlobal’s LifeSphere Safety MultiVigilance™ solution leads the way in transforming safety case management through technology and regulatory expertise.
Learn MoreArtificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world…
Learn MoreChicago, Illinois, July 19, 2017 – Dr. Vivek Ahuja, Vice President, Global Pharmacovigilance, ArisGlobal will present “Automation in ICSR Processing…
Learn MoreThe clinical trial sector witnessed a lot of action in 2016. Pharmaceutical establishments are increasing their focus on this branch…
Learn MoreSilos have long plagued the life sciences industry, and nowhere is this more notable than with how information and data…
Learn MoreArisGlobal LifeSphere® the most complete cognitive computing platform transforms every primary function of the product lifecycle including pharmacovigilance, clinical operations, clinical data management, regulatory affairs and medical communications
Learn MoreCUSTOMER BACKGROUND With a history dating back to the late 1980s, this western U.S. biopharmaceutical company has focused its development…
Learn More